Opiant Pharmaceuticals Inc (NASDAQ:OPNT) CEO Roger Crystal sold 10,847 shares of the company’s stock in a transaction that occurred on Tuesday, October 9th. The shares were sold at an average price of $17.21, for a total transaction of $186,676.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Roger Crystal also recently made the following trade(s):
- On Thursday, October 4th, Roger Crystal sold 18,450 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $18.11, for a total transaction of $334,129.50.
Shares of OPNT opened at $17.14 on Friday. Opiant Pharmaceuticals Inc has a 12 month low of $12.75 and a 12 month high of $48.00. The firm has a market cap of $53.27 million, a PE ratio of 5.61 and a beta of 0.18.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its quarterly earnings results on Thursday, August 9th. The technology company reported ($0.52) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.55. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 471.43%. The company had revenue of $3.15 million for the quarter, compared to analyst estimates of $2.10 million. Research analysts forecast that Opiant Pharmaceuticals Inc will post -5.4 earnings per share for the current year.
An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Northern Trust Corp purchased a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 24,372 shares of the technology company’s stock, valued at approximately $350,000. Northern Trust Corp owned about 0.86% of Opiant Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 4.76% of the company’s stock.
Several research analysts have weighed in on the stock. Cantor Fitzgerald set a $42.00 price objective on shares of Opiant Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 4th. ValuEngine lowered shares of Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Article: What is the S&P 500 Index?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.